

# Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234

NCT07453602

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Phase 1
<b>Sponsor</b>	Arcutis Biotherapeutics, Inc.
<b>Enrollment</b>	125 participants

## Key Eligibility Criteria

---

### Inclusion (8)

- Able and willing to provide written informed consent.
  - Adults 18-65 years (inclusive) at consent.
  - Generally healthy at screening/baseline (no clinically significant findings on medical history, exam, vitals, ECG, or safety labs, per investigator).
  - Contraception requirements: Females of childbearing potential: negative pregnancy tests at screening and baseline and agree to use highly effective contraception (plus barrier method) during the study and for 4 months after last dose. Males if sexually active with a pregnant partner or a female of childbearing potential, agree to condom use during the study and for 4 months after last dose.
  - Body weight by study part: Part A (SAD) \& Part B (MAD): 50-100 kg (inclusive), Part C (POC): 50-125 kg (inclusive)
- ... and 3 more (see full listing online)

### Exclusion (26)

- Any clinically significant medical or psychiatric condition that could increase risk, interfere with participation, or confound results (per investigator).
  - Significant renal impairment or clinically significant hepatic impairment (per protocol/part-specific definitions).
  - Clinically significant cytopenias or clinically significant abnormal liver tests at screening (per protocol).
  - History of anaphylaxis/serious hypersensitivity (including significant hypersensitivity to local anesthetics).
  - History of attempted suicide or significant current risk, per investigator).
- ... and 21 more (see full listing online)

## Locations (1 total)

---

Clinical Site 101, Fair Lawn, New Jersey, United States